Piper Sandler Maintains Overweight on Corcept Therapeutics, Raises Price Target to $31
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem maintains an Overweight rating on Corcept Therapeutics (NASDAQ:CORT) and raises the price target from $27 to $31.
August 04, 2023 | 1:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler's raised price target for Corcept Therapeutics indicates a positive outlook for the company's stock.
The raised price target by Piper Sandler from $27 to $31 indicates a positive outlook for Corcept Therapeutics. This suggests that the analyst believes the company's stock is undervalued at its current price and has the potential to rise, which could lead to a positive impact on the stock's short-term price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100